Physician profile
Zeina Rabi
NPI 1205179744
$6,776.49
in general payments reported to CMS, 2019-2025
40 companies · $1,058 in 2025
The $1,058 reported for 2025 was more than what a typical Clinical Neurophysiology provider received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $818 · 2020: $304 · 2021: $909 · 2022: $1,357 · 2023: $1,350 · 2024: $980 · 2025: $1,058.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,362 · Education: $26.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,362.42 |
| Education | $26.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $1,474.34 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Abbvie INC. | $1,333.94 | 2021-2025 | |
| Celgene Corporation | $638.58 | 2021-2025 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $629.22 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Acadia Pharmaceuticals INC | $276.86 | 2022-2025 | Nuplazid |
| Genentech USA, INC. | $204.38 | 2023-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Argenx US, INC. | $176.01 | 2022-2025 | Vyvgart Hytrulo |
| Novartis Pharmaceuticals Corporation | $171.77 | 2021-2024 | |
| Ucb, INC. | $168.21 | 2019-2024 | Nayzilam, Briviact |
| Pfizer INC. | $146.52 | 2023-2025 | |
| Amgen INC. | $144.73 | 2019-2022 | |
| Banner Life Sciences, LLC | $135.94 | 2021-2024 | |
| Sk Life Science, INC. | $120.63 | 2021-2025 | |
| Lilly USA, LLC | $116.36 | 2023-2025 | Amyvid, Reyvow, Emgality |
| Lundbeck LLC | $109.18 | 2023-2025 | Vyepti, Rexulti |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zeina Rabi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.